Literature DB >> 20673013

Human papillomavirus vaccines in plants.

Colomba Giorgi1, Rosella Franconi, Edward P Rybicki.   

Abstract

Human papillomaviruses are the etiological agents of cervical cancer, one of the two most prevalent cancers in women in developing countries. Currently available prophylactic vaccines are based on the L1 major capsid protein, which forms virus-like particles when expressed in yeast and insect cell lines. Despite their recognized efficacy, there are significant shortcomings: the vaccines are expensive, include only two oncogenic virus types, are delivered via intramuscular injection and require a cold chain. Plant expression systems may provide ways of overcoming some of these problems, in particular the expense. In this article, we report recent promising advances in the production of prophylactic and therapeutic vaccines against human papillomavirus by expression of the relevant antigens in plants, and discuss future prospects for the use of such vaccines.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20673013     DOI: 10.1586/erv.10.84

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  13 in total

1.  Using the omega leader sequence of tobacco mosaic virus to transform tomato fruits with the papillomavirus hpv16 L1 gene to enhance production of the antigenic protein HPV16 L11.

Authors:  R K Salyaev; N I Rekoslavskaya; A S Stolbikov; A V Tret'yakova
Journal:  Dokl Biochem Biophys       Date:  2016-07-15       Impact factor: 0.788

2.  Immunotherapy in new pre-clinical models of HPV-associated oral cancers.

Authors:  Francesca Paolini; Silvia Massa; Isabella Manni; Rosella Franconi; Aldo Venuti
Journal:  Hum Vaccin Immunother       Date:  2013-01-07       Impact factor: 3.452

3.  Translational fusion and redirection to thylakoid lumen as strategies to enhance accumulation of human papillomavirus E7 antigen in tobacco chloroplasts.

Authors:  Mauro Morgenfeld; Ezequiel Lentz; María Eugenia Segretin; E Federico Alfano; Fernando Bravo-Almonacid
Journal:  Mol Biotechnol       Date:  2014-11       Impact factor: 2.695

4.  In planta production of a candidate vaccine against bovine papillomavirus type 1.

Authors:  Andrew J Love; Sean N Chapman; Slavica Matic; Emanuela Noris; George P Lomonossoff; Michael Taliansky
Journal:  Planta       Date:  2012-06-21       Impact factor: 4.116

Review 5.  Human papillomavirus and cervical cancer.

Authors:  Kehinde Sharafadeen Okunade
Journal:  J Obstet Gynaecol       Date:  2019-09-10       Impact factor: 1.246

6.  A Chlamydomonas-derived Human Papillomavirus 16 E7 vaccine induces specific tumor protection.

Authors:  Olivia C Demurtas; Silvia Massa; Paola Ferrante; Aldo Venuti; Rosella Franconi; Giovanni Giuliano
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

7.  Efficient production of chimeric human papillomavirus 16 L1 protein bearing the M2e influenza epitope in Nicotiana benthamiana plants.

Authors:  Slavica Matić; Riccardo Rinaldi; Vera Masenga; Emanuela Noris
Journal:  BMC Biotechnol       Date:  2011-11-15       Impact factor: 2.563

Review 8.  Plant-based vaccines against viruses.

Authors:  Edward P Rybicki
Journal:  Virol J       Date:  2014-12-03       Impact factor: 4.099

9.  LALF32-51 -E7, a HPV-16 therapeutic vaccine candidate, forms protein body-like structures when expressed in Nicotiana benthamiana leaves.

Authors:  Romana J R Yanez; Renate Lamprecht; Milaid Granadillo; Isis Torrens; Elsa Arcalís; Eva Stöger; Edward P Rybicki; Inga I Hitzeroth
Journal:  Plant Biotechnol J       Date:  2017-09-07       Impact factor: 9.803

Review 10.  Reconceptualizing cancer immunotherapy based on plant production systems.

Authors:  Kathleen Hefferon
Journal:  Future Sci OA       Date:  2017-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.